Three Agencies Could Define GLP-1 Friendly. None Has.

2 hours ago 7

Rommie Analytics

By HANA KAHLEOVA

Almost every week, a patient asks me some version of the same question. If drugs like Ozempic work by copying a hormone my gut already makes, can the right food do what the injection does?

Food and supplement marketers have already answered yes. Frozen dinners now carry GLP-1 Friendly badges. Supplement ads promise the drug’s effects in a capsule. Hundreds of products invoke the hormone, aimed at the roughly 12 percent of U.S. adults who have taken one of these medications. Yet the term has no federal definition. The U.S. Department of Agriculture, which has approved the phrase on some labels, has stressed that its approvals do not create a standard. In March, Kyle Diamantas, then the Food and Drug Administration’s top food official and now its acting commissioner, told Bloomberg Law the agency was aware of the issue but had no action planned.

The result is a marketing claim that borrows the name of a hormone, falls between three regulators and has been tested by none of them. For a health system still deciding who should get these drugs and who should pay for them, that is not a side issue. It shapes what patients think they can buy instead.

What the Science Supports

As a clinical researcher who studies diet and type 2 diabetes, I think the honest answer is more interesting than the label. Food really can raise the body’s own GLP-1. The hormone is released by cells lining the intestine within minutes of a meal and, hours later, in response to compounds gut bacteria make from fiber.

But the evidence does not support single-ingredient claims. A scoping review published in July gathered 52 trials of isolated fibers. Most tested a single dose, the typical trial enrolled 19 people, and fewer than a third found any rise in GLP-1.

The strongest signal my colleagues and I have found came from a whole meal. In a randomized crossover trial, 60 men, 20 of them with type 2 diabetes, ate two breakfasts with the same calories and proportions of carbohydrate, protein and fat: a tofu burger with green tea, or a processed pork-and-cheese burger with a sweetened latte. After the plant-based meal, GLP-1 secretion was 30.5 percent higher in the men with diabetes, and measures of insulin secretion and beta-cell function improved. The meals also differed in fiber, saturated fat and sugar, so we cannot say which difference mattered. What moved the hormone was a pattern of eating, not a molecule.

Even the order of foods on a plate matters. In a small crossover trial in Japan, people with type 2 diabetes who ate fish or meat 15 minutes before rice had higher GLP-1 levels, slower stomach emptying and smaller blood sugar swings than when they ate the rice first. None of these effects comes from a product, and none of them fits on a sticker.

There is also a limit that matters for any claim of equivalence. The GLP-1 the gut makes survives only a minute or two in the bloodstream. The drugs are engineered to resist breakdown and keep the receptor occupied around the clock, at levels the body never produces on its own. A meal delivers a pulse. A weekly injection delivers a steady flood.

A Claim Between Three Regulators

Each agency with a stake in these labels has a tool that could address them. None is being used.

The USDA’s Food Safety and Inspection Service must approve special statements and claims on meat and poultry labels before they are used. That gives it a gatekeeping role the other agencies lack. Yet FSIS has approved GLP-1 claims without saying what they mean, and as of June, five companies had filed 21 more label requests for meat and poultry products.

The FDA governs most other foods and supplements, but its framework offers little resistance. Conventional food makers may make structure/function claims without notifying the agency. Supplement makers need only notify the FDA within 30 days of marketing and add a disclaimer that the agency has not evaluated the claim. A label saying a product supports GLP-1 can fit comfortably in that space, even when it implies something closer to treating obesity or diabetes. The agency has not been idle on GLP-1 marketing. It has sent repeated rounds of warning letters to telehealth companies over misleading claims about compounded versions of the drugs. But that campaign targets drug sellers. The foods and supplements that borrow the hormone’s name have not drawn the same scrutiny.

The Federal Trade Commission polices advertising. Its 2022 Health Products Compliance Guidance says health claims require competent and reliable scientific evidence, generally randomized, controlled human trials, and in some cases a study of the actual product rather than an isolated ingredient. Few GLP-1 marketing claims appear to meet that bar. The commission has shown it will act in this market: last December it finalized an order against a telehealth company over unsubstantiated weight-loss claims and fake reviews tied to the drugs. It has declined to say whether it is looking at food and supplement claims.

Why It Matters

This is not a harmless sticker. A shopper who sees GLP-1 Friendly on a frozen pizza may assume it does something it was never tested to do. A patient who believes a capsule can stand in for a prescription may stop a drug she needs; one obesity physician told Bloomberg Law she had just seen exactly that. And a patient on the drug may miss what food can genuinely offer: a better hormone response, steadier blood sugar and real fullness.

What Clinicians and Payers Can Do

The patients most exposed to these claims are often the ones who cannot get the drug. According to the Business Group on Health, the share of large employers covering GLP-1 drugs for weight management fell from 72 percent in 2025 to 60 percent this year, and 14 percent have dropped that coverage or plan to in 2027. When coverage ends, the demand does not. Some of it will land in the supplement aisle, where labels promise the drug’s effect for the price of a bottle.

Clinicians can close part of that gap in the exam room. We already ask patients which supplements they take. We should ask specifically about products sold as GLP-1 boosters or drug alternatives, especially when a patient has stopped a GLP-1 or lost coverage for one. As I argued here recently, short visits make the prescription the default. They also leave little time to ask what a patient bought on the way home. That question opens the conversation about what food can honestly do.

Payers can make the honest version easier to reach. A plan that drops a drug and offers nothing in its place leaves patients to the marketers. Medicare covers medical nutrition therapy only for people with diabetes or kidney disease, or a kidney transplant in the past 36 months. Many employers that still cover the drugs already require patients to join a weight management program. Those programs, and plans that have dropped coverage, should pay for counseling with a registered dietitian, so patients learn what a meal can do for their own hormone response whether or not they stay on the drug.

Three Fixes

First, FSIS should stop approving GLP-1 claims until it defines them, and any definition should require human evidence: tested on the product, measuring the hormone itself, at the amount people actually eat.

Second, the FDA should issue guidance stating that claims comparing a food or supplement to GLP-1 drugs, or promising drug-like effects on weight or blood sugar, are implied disease claims rather than structure/function claims. That would move the most misleading claims out of the lightly policed category they now occupy.

Third, the FTC should apply its existing substantiation standard to GLP-1 marketing, starting with warning letters to the most aggressive supplement claims. It does not need new authority to do so.

Better still, the three agencies should coordinate, so that a claim cannot escape scrutiny by moving from a meat label to a supplement bottle to an online ad.

Decades of research have taught us that GLP-1 is a signal with a timescale, a location and a dose. A sticker flattens all three. Food can do more than most people think, and less than the labels promise. Patients, and the clinicians and health plans who care for them, deserve the honest version of both.

Hana Kahleova, MD, PhD, is a physician board-certified in internal medicine, endocrinology and lifestyle medicine, and director of clinical research at the Physicians Committee for Responsible Medicine, a nonprofit that promotes plant-based nutrition and preventive medicine. She led the plant-based meal studies described here and reports no financial relationships with food, supplement or pharmaceutical companies.

Read Entire Article